Evidence map›Paper›PMID 27566899›Full record

ArticleVaccine2016

Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization.

Pablo Penaloza-MacMaster, Quazim A Alayo, Joshua Ra, Nicholas M Provine, Rafael Larocca, Benjamin Lee, Dan H Barouch

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Pre-existing immunity modulates responses to mRNA boosters.bioRxiv : the preprint server for biology · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pablo Penaloza-MacMasterCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
Quazim A AlayoCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
Joshua RaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
Nicholas M ProvineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
Rafael LaroccaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
Benjamin LeeCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States; Ragon Institute of MGH, MIT, and Harvard, Boston, MA 02114, United States. Electronic address: dbarouch@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USRagon Institute of MGH, MIT and Harvard · US

Funding

Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 VaccineU19AI078526 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2008 to 2012
$44.0M
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 VaccinesU19AI096040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SEAMAN, MICHAEL SCOTT · 2012 to 2016
$18.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
NIAID NIH HHS T32 AI007245NIAID NIH HHS T32 AI007387NIAID NIH HHS U19 AI078526NIAID NIH HHS U19 AI096040
6 · The paper itself

Abstract

T cells are an important component of immune responses, and their function is influenced by their expression of inhibitory receptors. Immunization with alternative serotype adenovirus (Ad) vectors induces highly functional T cell responses with lower programmed cell death 1 (PD-1) expression and increased boostability relative to Ad5 vectors. However, a detailed phenotypic characterization of other inhibitory receptors is lacking, and it is unknown whether Ad5-induced CD8 T cells eventually recover function with time. In this report, we measure the expression of various inhibitory receptors and memory markers during early and late time points following vaccination with Ad5 and alternative serotype Ad vectors. CD8 T cells induced by Ad5 exhibited increased expression of the inhibitory receptor Tim-3 and showed decreased central memory differentiation as compared with alternative serotype Ad vectors, even a year following immunization. Moreover, relative to Ad5-primed mice, Ad26-primed mice exhibited substantially improved recall of SIV Gag-specific CD8 T cell responses following heterologous boosting with MVA or Ad35 vectors. We also demonstrate that low doses of Ad5 priming resulted in more boostable immune responses with lower PD-1 expression as compared to high Ad5 doses, suggesting a role for vector dose in influencing immune dysfunction following Ad5 vaccination. These data suggest that Ad5 vectors induce a long-term pattern of immune exhaustion that can be partly overcome by lowering vector dose and modulating inhibitory signals.

Indexed as

AdenoviridaeGenetic VectorsImmunologic MemoryAnimalsCD8-Positive T-LymphocytesCytokinesFemaleHepatitis A Virus Cellular Receptor 2ImmunizationMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorCytokinesHavcr2 protein, mouseHepatitis A Virus Cellular Receptor 2Pdcd1 protein, mouseProgrammed Cell Death 1 ReceptorAdenovirusHIV-1PD-1Vector

Identifiers

PMID27566899
PMCPMC5038157
OpenAlexW2512353104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.